Drug Combination Details
| General Information of the Combination (ID: C10234) | |||||
|---|---|---|---|---|---|
| Name | Gossypol NP Info | + | TRAIL/Apo2L Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Esophageal cancer
[ICD-11: 2B70]
|
Investigative | [1] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
| NCI-H322 | CVCL_1556 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Gossypol profoundly sensitizes thoracic cancer cells to the cytotoxic effect of Apo2L/TRAIL via activation of the mitochondria-dependent death signaling pathway. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP9 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | TE-2 | CVCL_4455 | Esophageal squamous cell carcinoma | Homo sapiens | ||
| TE-12 | CVCL_1762 | Esophageal squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Gossypol profoundly sensitizes thoracic cancer cells to the cytotoxic effect of Apo2L/TRAIL via activation of the mitochondria-dependent death signaling pathway. | |||||
